Meibomian Blepharitis – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Meibomian Blepharitis – Drugs In Development, 2024 report and make more profitable business decisions.
Meibomian blepharitis or Meibomian gland dysfunction (MGD) is a condition that causes low-grade inflammation of the eyelids. It can also lead to obstruction of the oil glands in the eyelid. It is caused by high cholesterol and triglycerides, allergic conjunctivitis and other eye diseases, inflamed or damaged eyelid or cornea, bacterial infection, and autoimmune diseases like rosacea, lupus, rheumatoid arthritis, and Sjögren’s syndrome. Symptoms include itching, burning sensation, redness, irritation, soreness of eyes, eyelid edema, and foreign body sensation. Treatment options include warm compresses, antibiotic or steroid eye drops, artificial tear eye drops, and oral antibiotics.
The Meibomian Blepharitis drugs in development market research report provide comprehensive information on the therapeutics under development for Meibomian Blepharitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Meibomian Blepharitis and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Meibomian Blepharitis | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 5 molecules, with 5 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Meibomian Blepharitis therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Meibomian Blepharitis pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Meibomian Blepharitis treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Alcon IncAzura Ophthalmics Pty Ltd
LianBio
Santen Pharmaceutical Co Ltd
Senju Pharmaceutical Co Ltd
Tarsus Pharmaceuticals Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Meibomian Blepharitis reports